The idea I had about research when I was growing up was entirely different from what exactly is the ground truth.
The Picture of a mad scientist working all alone, with test tubes Containing solutions with wonderful colors and bubbly flasks, beakers and Bunsen burners trying to find "THE CURE "
is no longer true.
The idea that research can be contracted was a total revelation to me.
CROs put a premium on time and speed. They assess the regulatory environments of prospective countries in at least two ways: on the basis of "country approval time" and "country activation time." The first term refers to the time it takes for companies to obtain approval to begin a clinical trial in a particular country. This is dependent on factors related to internal government bureaucracy, the quality of national and local ethics committees and inspection regimes, and procedures and authorizations involved in drug importing. The second term refers to the time it takes for a company to get a study up and running. This involves finding centers of research excellence, training personnel, recruiting patients, and shipping experimental compounds to the sites. Approval and activation times inform a fluid map of locations where, at any given moment, trials could be quickly launched that would result in high-quality clinical data. The same terms also identify countries that should be pursued further or invested in (as well as sites that should be avoided) and countries in which the drug under study could be marketed.
Where is India in comparison to other Hot CRO outsourcing countries?
The Picture of a mad scientist working all alone, with test tubes Containing solutions with wonderful colors and bubbly flasks, beakers and Bunsen burners trying to find "THE CURE "
is no longer true.
The idea that research can be contracted was a total revelation to me.
CROs put a premium on time and speed. They assess the regulatory environments of prospective countries in at least two ways: on the basis of "country approval time" and "country activation time." The first term refers to the time it takes for companies to obtain approval to begin a clinical trial in a particular country. This is dependent on factors related to internal government bureaucracy, the quality of national and local ethics committees and inspection regimes, and procedures and authorizations involved in drug importing. The second term refers to the time it takes for a company to get a study up and running. This involves finding centers of research excellence, training personnel, recruiting patients, and shipping experimental compounds to the sites. Approval and activation times inform a fluid map of locations where, at any given moment, trials could be quickly launched that would result in high-quality clinical data. The same terms also identify countries that should be pursued further or invested in (as well as sites that should be avoided) and countries in which the drug under study could be marketed.
Where is India in comparison to other Hot CRO outsourcing countries?
No comments:
Post a Comment